Author | Mark H. O'Hara, MD | OncLive

Author | Mark H. O'Hara, MD


Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

April 26, 2019


Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.